Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Has Gilead Sciences, Inc. (GILD) Become the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing’s for sure: You’ll never discover truly great investments unless you actively look for them. Let’s discuss the ideal qualities of a perfect stock, then decide if Gilead Sciences, Inc. (NASDAQ:GILD) fits the bill.

Gilead Sciences, Inc. (NASDAQ:GILD)The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

1). Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it’s certainly a better sign than a stagnant top line.

2). Margins. Higher sales mean nothing if a company can’t produce profits from them. Strong margins ensure that company can turn revenue into profit.

3). Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management’s attention. Companies with strong balance sheets don’t have to worry about the distraction of debt.

4). Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.

5). Valuation. You can’t afford to pay too much for even the best companies. By using normalized figures, you can see how a stock’s simple earnings multiple fits into a longer-term context.

6). Dividends. For tangible proof of profits, a check to shareholders every three months can’t be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let’s take a closer look at Gilead Sciences.

Factor What We Want to See Actual Pass or Fail?
Growth 5-year annual revenue growth > 15% 18.1% Pass
1-year revenue growth > 12% 15.7% Pass
Margins Gross margin > 35% 74.5% Pass
Net margin > 15% 26.7% Pass
Balance sheet Debt to equity < 50% 77.7% Fail
Current ratio > 1.3 1.42 Pass
Opportunities Return on equity > 15% 31.4% Pass
Valuation Normalized P/E < 20 27.01 Fail
Dividends Current yield > 2% 0% Fail
5-year dividend growth > 10% 0% Fail
Total score 6 out of 10

Source: S&P Capital IQ. Total score = number of passes.

Since we looked at Gilead Sciences last year, the company has stayed stuck at six points, unable to regain the point it lost from 2011 to 2012. But the stock has soared more than 50% over the past year on enthusiasm about its future prospects.

One of the biggest growth areas for Gilead over the past year came from its massive acquisition of Pharmasset just over a year ago. With its GS-7977/sofosbuvir drug for treating hepatitis C, Gilead has taken the lead in the hep-C market, as other players have suffered some dramatic flameouts. Bristol Myers Squibb Co. (NYSE:BMY) made its own big hep-C acquisition, but the experimental drug turned out to cause one patient death and complications with others, forcing the company to drop development. Meanwhile, Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) had two of its hep-C prospects put on clinical holds back in November due to safety concerns, and Idenix said earlier this week that it would not continue clinical development programs for the IDX184 and IDX19368 drug candidates.

By contrast, sofosbuvir has demonstrated strong results, and the fact that it’s an all-oral treatment bodes well for its competitive prospects against interferon-reliant treatments from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Merck & Co., Inc. (NYSE:MRK) , which require intravenous administration and can cause flu-like symptoms for nearly a year during treatment. With two phase-3 trials succeeding in hitting primary endpoints, sofosbuvir is setting up to be a big part of Gilead’s future.

In its most recent quarter, Gilead again demonstrated the power of its HIV/AIDS treatments while showing a pathway to future growth in other areas. Strong growth from the oncology and cardiovascular areas are dovetailing well with the company’s overall strategy and show few signs of letting up.

For Gilead to improve, it needs to work on getting its debt levels down a bit while translating its growth prospects into higher earnings. That won’t get it to perfection, but it’ll be a big step in Gilead’s steady climb to prominence in the industry.

The article Has Gilead Sciences Become the Perfect Stock? originally appeared on and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.